- Research works
- 100 ▲ 3060% vs 2013–17
- Citations
- 965 9.7 per fractional work
- Top-10% rate
- 14.8% record average 16.5%
- Open access
- 52% world 28%
Not ranked overall: Genecast (China) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
What does Genecast (China) specialise in?
Where its research is concentrated relative to its size: Medicine takes 3.7× the share of its output that it takes of world research.
- MedicineField · 31.2 works3.7×
- Health SciencesDomain · 31.4 works3.1×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 4.8×. Every wedge is a field page.
Who are the top researchers at Genecast (China)?
Ranked on the composite score, Weizhi Chen and Henghui Zhang lead among researchers whose main affiliation is Genecast (China).
- 1 Weizhi Chen China · #304,151 worldwide 61 citations · 25 works
- 2 Henghui Zhang China · #408,162 worldwide 63 citations · 19 works
Which keywords describe research at Genecast (China)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Targeted Therapy, Chemotherapy, Tumor Microenvironment, Clinical Trials, Cancer Genomics, Mutational Signatures, Immune Checkpoint Blockade and PD-1 and PD-L1.
- Tumor Staging
- DNA Methylation
- BRAF Mutation
- Barrett's Esophagus
- Survival Analysis
- Small-Cell Lung Cancer
- Cetuximab
- Clinical Practice Guidelines
- Adjuvant Therapy
- Precision Medicine
- Gene Expression
- Biomarkers
- Radiotherapy
- Cancer
- Immunotherapy
- EGFR Mutations
- PD-1 and PD-L1
- Mutational Signatures
- Clinical Trials
- Chemotherapy
- Targeted Therapy
- Tumor Microenvironment
- Cancer Genomics
- Immune Checkpoint Blockade
- ALK Inhibitors
- Prognostic Factors
- Neoadjuvant Therapy
- Metastasis
- Tumor Markers
- Endoscopic Resection
- Molecular Characterization
- Preoperative Chemoradiotherapy
- Chemoradiation
- Surgery
- Genomic Profiles
- Molecular Subtypes
- Adjuvant Chemotherapy
- Esophageal Carcinoma
- Cell Death
- Histone Modification
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Targeted Therapy12▲ 117×3 topics
- Chemotherapy8▲ 27×12 topics
- Tumor Microenvironment8▲ 42×6 topics
- Clinical Trials6▲ 21×3 topics
- Cancer Genomics6▲ 178×1 topic
- Mutational Signatures6▲ 178×1 topic
- Immune Checkpoint Blockade5▲ 107×1 topic
- PD-1 and PD-L15▲ 107×1 topic
- ALK Inhibitors4▲ 138×1 topic
- EGFR Mutations4▲ 138×1 topic
- Prognostic Factors4▲ 19×8 topics
- Immunotherapy4▲ 12×8 topics
- Neoadjuvant Therapy4▲ 34×5 topics
- Cancer3▲ 5.0×12 topics
- Metastasis3▲ 18×6 topics
- Radiotherapy2▲ 14×3 topics
- Tumor Markers2▲ 70×2 topics
- Biomarkers2▲ 8.0×3 topics
- Endoscopic Resection2▲ 54×2 topics
- Gene Expression2▲ 9.0×6 topics
- Molecular Characterization2▲ 31×4 topics
- Precision Medicine2▲ 11×2 topics
- Preoperative Chemoradiotherapy2▲ 62×2 topics
- Adjuvant Therapy2▲ 37×2 topics
- Chemoradiation2▲ 73×2 topics
- Clinical Practice Guidelines2▲ 8.8×6 topics
- Surgery2▲ 13×2 topics
- Cetuximab2▲ 54×2 topics
- Genomic Profiles2▲ 109×1 topic
- Small-Cell Lung Cancer2▲ 109×1 topic
- Molecular Subtypes2▲ 50×2 topics
- Survival Analysis2▲ 15×6 topics
- Adjuvant Chemotherapy2▲ 56×2 topics
- Barrett's Esophagus2▲ 96×1 topic
- Esophageal Carcinoma2▲ 96×1 topic
- BRAF Mutation2▲ 47×2 topics
- Cell Death2▲ 14×2 topics
- DNA Methylation2▲ 30×1 topic
- Histone Modification2▲ 49×1 topic
- Tumor Staging2▲ 30×2 topics
Which research topics does Genecast (China) publish most on?
By volume in 2022–2025: Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations and Lung Cancer Research Studies.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Cancer Genomics and Diagnostics Cancer Research 6 works
- 2 Cancer Immunotherapy and Biomarkers Oncology 5 works
- 3 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 4 works
- 4 Lung Cancer Research Studies Oncology 2 works
- 5 Esophageal Cancer Research and Treatment Surgery 2 works
- 6 Epigenetics and DNA Methylation Molecular Biology 2 works
- 7 Ferroptosis and cancer prognosis Pulmonary and Respiratory Medicine 1 works
- 8 Colorectal Cancer Treatments and Studies Oncology 1 works
- 9 Lung Cancer Diagnosis and Treatment Pulmonary and Respiratory Medicine 1 works
- 10 Genetic factors in colorectal cancer Pathology and Forensic Medicine 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Genecast (China)'s research output changed?
Output in 2018–2022 was 3060% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Beijing
- Chinese Academy of Sciences
- Tsinghua University
- Peking University
- University of Chinese Academy of Sciences
- Beihang University
- Beijing Institute of Technology
- Chinese Academy of Medical Sciences & Peking Union Medical College
- North China Electric Power University
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.